Case Comprehensive Cancer Center: Lymphoma, Non-Hodgkin trials

The registry lists 17 Lymphoma, Non-Hodgkin studies with Case Comprehensive Cancer Center as lead sponsor. 0 are open to participants now and 5 have results posted.

Early Phase 1 2Phase 1 4Phase 2 9Phase 3 1No phase 2(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Carfilzomib, Rituximab, and Combination Chemotherapy in Treating Patients With Diffuse Large B-Cell LymphomaCompletedNCT02073097Phase 1/2Results posted
• Yttrium Y 90 Ibritumomab Tiuxetan and Rituximab in Primary Central Nervous System Non-Hodgkin LymphomaTerminatedNCT01973062Phase 2Results posted
• Tac, Mini-MTX, MMF Versus Tac, MTX for GVHD PreventionCompletedNCT01951885Phase 3Results posted
• Etoposide, Filgrastim, and Plerixafor in Improving Stem Cell Mobilization in Treating Patients With Non-Hodgkin LymphomaTerminatedNCT01408043Not applicableResults posted
• Donor Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic MalignanciesCompletedNCT01093586Phase 2Results posted
• Venetoclax in Combination With BEAM Conditioning Regimen for ASCT in Non-Hodgkin LymphomaCompletedNCT03713580Phase 1
• Intra-Osseous Co-Transplant of UCB and hMSCCompletedNCT02181478Early Phase 1
• Dose Monitoring of Busulfan and Combination Chemotherapy in Hodgkin or Non-Hodgkin Lymphoma Undergoing Stem Cell TransplantCompletedNCT01959477Early Phase 1
• Methoxyamine and Fludarabine Phosphate in Treating Patients With Relapsed or Refractory Hematologic MalignanciesCompletedNCT01658319Phase 1
• High-Dose Busulfan and High-Dose Cyclophosphamide Followed By Donor Bone Marrow Transplant in Treating Patients With Leukemia, Myelodysplastic Syndrome, Multiple Myeloma, or Recurrent Hodgkin or Non-Hodgkin LymphomaCompletedNCT01177371Phase 2
• Lenalidomide And Rituximab as Maintenance Therapy in Treating Patients With B-Cell Non-Hodgkin LymphomaTerminatedNCT01045928Phase 1
• Positron Emission Tomography Using Fludeoxyglucose F 18 in Predicting Response to Treatment in Patients Who Are Receiving Rituximab and Combination Chemotherapy for Newly Diagnosed Non-Hodgkin's LymphomaWithdrawnNCT00110006Not applicable
• Molecular Risk Assessment in Planning Treatment for Patients With Non-Hodgkin's LymphomaCompletedNCT00055640Phase 2
• Combination Chemotherapy in Treating Patients With AIDS-Related Non-Hodgkin's LymphomaCompletedNCT00049439Phase 2
• Cyclophosphamide W/or W/Out Rituximab and Peripheral Stem Cell Transplantation in Patients With Recurrent Non-Hodgkin's LymphomaCompletedNCT00028665Phase 2
• Oral Combination Chemotherapy in Treating Elderly Patients With Intermediate or High-Grade Non-Hodgkin's LymphomasTerminatedNCT00003113Phase 2
• Bleomycin in Treating Patients With Non-Hodgkin's LymphomaCompletedNCT00003110Phase 2